Cellectis SA (ALCLS.PA)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|53||2000||Chairman of the Board, Chief Executive Officer|
|2014||Chief Financial Officer|
|2018||Chief Operating Officer, Executive Vice President - Strategy and Corporate Development|
|2008||Executive Vice President-Corporate Development, Director|
|2017||Senior Vice President - Research and Development and Chief Medical Officer|
- BRIEF-Cellectis Operating Loss Widens To 21.7 Million US Dollars
- BRIEF-Cellectis Publishes Methods to Improve Clinical Use of Chimeric Antigen Receptor T-Cell Therapy
- BRIEF-Cellectis Announces Approval Of Amendment To Protocol For UCART123 Phase 1 Clinical Trial
- BRIEF-Cellectis Submits Investigational New Drug Application To FDA For UCART22
- BRIEF-Cellectis Partners With Harvard’S Wyss Institute For Research On Human Genome